Clinical Trial Update: A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body [Phase 1]

View source ↗

Summary

This Phase 1 update describes the safety and tolerability of ND-L02-s0201 in fibrosis, along with its effects on the body.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis

Drugs mentioned

• ND-L02-s0201

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Fibrosis | Phase 1 | Status: COMPLETED